Collegium Pharmaceutical stock inched up 1.2% to US$29.47 after earnings, a muted move for a company that just swung from a Q1 profit to a Q2 loss. The market focused on the headline net loss of US$15.1m, yet the more important story for you is the margin squeeze behind that number.

Revenue in Q2 came in at US$199.9m, supported by the expanding attention deficit hyperactivity disorder portfolio. However, acquisition costs and authorized generics in pain treatments pressured profitability. The key question now is how those compressed margins shape the multi year earnings path you are really investing in.

Love the revenue base Collegium Pharmaceutical is building but concerned about the margin squeeze and acquisition drag on earnings? Check out our list of list of solid balance sheet and fundamentals stocks (49 results) to compare COLL with companies that pair sales strength with tighter cost control.

Q2 2026 Earnings Summary

• Revenue Q2 2026 vs. Q2 2025: US$199.9m vs. US$188.0m (up about 6%)
• Net Income/Loss Q2 2026 vs. Q2 2025: loss of US$15.1m vs. profit of US$12.0m (swing to loss)
• Basic EPS Q2 2026 vs. Q2 2025: loss of US$0.46 per share vs. profit of US$0.38 per share (swing to loss)
• Adjusted EBITDA Q2 2026 vs. Q2 2025: US$113.8m vs. about US$105.4m (up about 8%)

Prefer clear visuals over slogging through another wall of earnings text and margin tables? View Collegium Pharmaceutical's complete financial picture in an easy-to-scan summary of its earnings and profitability trends in the company report for Collegium Pharmaceutical.

Collegium bull case tested by ADHD momentum

Bulls argue Collegium Pharmaceutical is evolving from a pain focused company into a more balanced CNS and ADHD platform that can support a higher quality revenue mix. Q2 gives concrete support to that view. Jornay PM revenue reached US$46.1m with prescriptions up 13.1% and prescribers above 30,000, up 17.6%. Branded long acting methylphenidate share moved to 29.2%, up 5.8 points, which signals real share gains rather than just pricing. The first full quarter with Azstarys contributed US$12.9m and led management to lift its 2026 revenue range for that product to US$65m to US$75m. Sales force expansion to about 190 reps and coverage of roughly 27,000 HCPs is in place ahead of the key back to school season. Together with 8% growth in adjusted EBITDA and management describing Azstarys as immediately earnings accretive, the diversification and CNS growth narrative is progressing on schedule.

Bear case focuses on margin strain and pain erosion

Bears worry that Collegium Pharmaceutical is too exposed to aging pain brands, rising fixed costs and rebate pressure that can eat into margins even if ADHD grows. Q2 supports those concerns. Total product revenue rose to US$199.9m, yet the company swung to a GAAP net loss of US$15.1m and guided adjusted EBITDA for 2026 to US$445m to US$470m, described as roughly flat versus 2025. That undercuts the idea of near term earnings expansion. NUCYNTA revenues declined 24% as authorized generic pricing reset the net price lower and management cut full year expectations for that franchise. Xtampza ER also declined year on year, helped last year by rebate timing, and pain now leans more heavily on Belbuca, which did grow to US$57.7m. With higher commercialization spend for the expanded ADHD field force and new Boston office commitments, the risk of sustained margin compression remains front and center.

After a swing from profit to loss, heavier fixed costs and large one off items raise a fair question. Review our independent risk analysis for Collegium Pharmaceutical which shows 3 important warning signs

Stay Ahead With Collegium Pharmaceutical

If the swing from profit to loss and margin pressure at Collegium Pharmaceutical has your attention, register for free with Simply Wall St and add it to your Watchlist to track price against fair value and watch how the thesis evolves. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the key earnings, risk and fundamental updates that matter most. For long term conviction building, lean on the Community to see how other investors are thinking about the same risks and potential catalysts. By catching both hidden pressure points and early positives, you can act sooner and stay ahead of the broader market.

Seeking Alternatives Beyond Collegium Pharmaceutical?

Fresh stock ideas do not stay under the radar for long. Once momentum builds, prices can be flying before most investors notice. Scan these screeners now and get in early.

• Hunt for resilient cash generators before they are widely followed by comparing Collegium Pharmaceutical with our curated list of solid balance sheet and fundamentals stocks (49 results) that already show disciplined balance sheets and steady fundamentals.
• Spot early AI momentum before it gets fully caught in the headlines by reviewing hand picked 68 profitable AI stocks that aren't just burning cash that pair revenue traction with real profitability.
• Target potential income workhorses while yields still look attractive by running through carefully filtered 8 dividend fortresses that combine robust balance sheets with payouts above 5%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.